Thrivent Financial for Lutherans reduced its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 33.0% in the fourth quarter, according to the company in its most recent 13F filing with ...

In trading on Wednesday, shares of Denali Therapeutics Inc (Symbol: DNLI) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $13.86 per share.

Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock ...

One stock that might be an intriguing choice for investors right now is Denali Therapeutics Inc. DNLI. This is because this ...

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) have been given a consensus recommendation of “Moderate ...

DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, tividenofusp alfa (DNL310), for the treatment of individuals with Hunter syndrome (MPS II).

Stay updated on market trends for DNLI. Denali Therapeutics' ALS drug DNL343 failed to show efficacy, leading to the discontinuation of the trial extension. Analysts now focus on its Hunter ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Denali Therapeutics (DNLI – Research Report), ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) today. The company’s ...

One stock that might be an intriguing choice for investors right now is Denali Therapeutics Inc. DNLI. This is because this security in the Medical - Biomedical and Genetics space is seeing solid ...